After the COVID-19 Pandemic, Rising Concerns Over Animal-to-Human Pathogen Spillover Drive Global Preparedness Efforts

In April 2026, a team of virologists from the University of Nairobi and the Kenya Medical Research Institute (KEMRI) reported the isolation of a novel bat coronavirus, designated BtCoV-KE2025, capable of binding to and entering human respiratory epithelial cells in vitro. This discovery emerged from a three-year surveillance program initiated in 2023 to monitor zoonotic spillover risks in regions with high bat biodiversity and increasing human-wildlife interface, particularly around caves in Kenya’s Rift Valley province. The virus, identified in fecal samples from Hipposideros bats, shares approximately 78% genomic similarity with SARS-CoV-2 but possesses a distinct receptor-binding domain (RBD) that demonstrates affinity for both angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) receptors in human cell lines—a dual tropism not previously documented in African bat coronaviruses.

Key Clinical Takeaways:

• BtCoV-KE2025 can infect human lung and intestinal cells using ACE2 and DPP4 receptors, indicating a potential for respiratory and gastrointestinal pathogenesis.
• The virus was detected in 12 of 318 bat samples (3.8% prevalence) across four cave systems in western Kenya, with no evidence of human infection to date.
• Ongoing research focuses on characterizing its transmissibility and immune evasion properties, with vaccine prototype development underway using mRNA and viral vector platforms.

The finding underscores a persistent gap in global pandemic preparedness: although genomic surveillance has expanded significantly since 2020, functional validation of zoonotic threats remains resource-intensive and unevenly distributed across regions. Most bat coronavirus studies rely on serological or PCR screening without assessing actual cellular infectivity, potentially underestimating spillover risk. BtCoV-KE2025’s ability to utilize two major human coronavirus receptors raises concerns about its adaptive potential, particularly if recombination events occur with circulating human coronaviruses in intermediate hosts. Such dual-receptor usage could broaden tissue tropism and influence clinical severity, though current data suggest the virus exhibits limited replication efficiency in primary human airway cultures compared to SARS-CoV-2.

Funded by a Wellcome Trust International Intermediate Fellowship and supplemented by the African Union’s Africa CDC Pathogen Genomics Initiative, the study employed pseudotyped virus assays and reverse genetics to evaluate entry mechanisms. Primary human lung adenocarcinoma (Calu-3) and colonic epithelial (Caco-2) cells were exposed to BtCoV-KE2025 spike protein-pseudotyped lentiviruses, revealing significant transduction efficiency that was neutralized by soluble ACE2 and DPP4 receptors, as well as polyclonal antibodies raised against the RBD. The research team, led by Dr. Amina Jallo, a virologist at KEMRI’s Centre for Virus Research, emphasized that receptor binding alone does not equate to transmissibility or pathogenicity in humans.

“While BtCoV-KE2025 shows concerning molecular compatibility with human cells, we have no evidence it can overcome the multiple biological barriers required for sustained human-to-human transmission. Surveillance must continue, but alarmism serves no public health purpose.”

Dr. Vincent Munster, Chief of the Virus Ecology Unit at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), who reviewed the findings independently, noted the importance of regional capacity building in pathogen discovery. “Studies like this highlight why investing in local diagnostic and sequencing infrastructure is critical,” he stated. “The earlier we detect and functionally characterize novel viruses at their source, the better positioned we are to develop countermeasures before spillover occurs.”

“Global health security depends not just on detecting outbreaks, but on identifying threats before they jump. Kenya’s investment in One Health surveillance is a model for proactive pandemic defense.”

The study’s methodology aligns with WHO’s R&D Blueprint guidelines for prioritizing pathogens with epidemic potential, particularly those demonstrating in vitro human cell infection. Although, experts caution against overinterpretation of in vitro data, stressing that viral fitness in humans depends on numerous factors beyond receptor binding, including immune evasion, replication kinetics, and environmental stability. To date, no human seroprevalence studies have been conducted in communities near the sampling sites, though plans are underway to collaborate with the Kenyan Ministry of Health on targeted serosurveys using multiplex antigen assays.

From a translational perspective, the identification of BtCoV-KE2025’s dual receptor usage has informed early-stage vaccine design efforts. Researchers at the University of Oxford’s Pandemic Sciences Institute, in collaboration with KEMRI, are evaluating whether chimeric antigens incorporating conserved epitopes from BtCoV-KE2025’s RBD could elicit broad-neutralizing antibody responses against sarbecoviruses and merbecoviruses. This approach mirrors strategies pursued for pan-coronavirus vaccines following the emergence of SARS-CoV-2 variants of concern.

For clinicians and public health officials operating in regions with active zoonotic surveillance, integrating laboratory findings with ecological and epidemiological data remains essential. Patients presenting with unexplained respiratory or gastrointestinal illness in endemic zones should prompt consideration of novel pathogens, though such diagnoses require specialized testing available only at reference laboratories. Timely access to expert consultation and advanced diagnostics is critical.

Individuals concerned about potential exposure to emerging infectious diseases—particularly those with occupational or recreational contact with wildlife—should seek guidance from specialists trained in travel medicine, infectious diseases, or public health prevention. For complex cases requiring differential diagnosis of atypical infections, consulting vetted infectious disease specialists ensures access to clinicians experienced in recognizing atypical presentations and coordinating with public health authorities. Similarly, healthcare institutions aiming to strengthen their outbreak readiness can benefit from engaging public health consultants who specialize in designing surveillance protocols and infection control frameworks tailored to local risk profiles.

As viral discovery accelerates through metagenomic sequencing and AI-driven risk modeling, the challenge lies not in detecting threats, but in distinguishing those with genuine pandemic potential from evolutionary dead ends. BtCoV-KE2025 serves as a reminder that preparedness must be grounded in rigorous science—not speculation—and that the most effective defenses are built long before a pathogen crosses the species barrier.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*